WASHINGTON, D.C. (April 12, 2002) - The three-day policy/ethics track at the Biotechnology Industry Organization’s (BIO) 16th Annual International Biotechnology Convention and Exhibition, BIO 2002, will feature ten sessions with more than 40 government, religious and research experts.
BIO 2002, June 9-12 at the Metro Toronto Convention Centre in Toronto, Ontario, is the world’s largest biotechnology event with more than 14,000 industry leaders expected to attend.
BIOETHICS HIGHLIGHTS (full track information)
Protection of Human Research Subjects - exploring issues such as informed consent, institutional review board and conflict of interest.
Greg Koski, M.D., director of the Office of Human Research Protections, Department of Health and Human Services
Heidi Wagner, director of government affairs, Genentech
Robert Goldberg, director of the Center for Medical Progress, Manhattan Institute
Religious Perspectives on Biotechnology - discussing the intersection of biotechnology with religion.
Dr. Bob Edgar, general secretary, National Council of Churches
Dr. John Haas, president, National Catholic Bioethics Center
Dr. Mohammed Lazzouni, director of interfaith relations, Islamic Society of Greater Worcester
Rabbi David Saperstein, director and counsel, Religious Action Center of Reform Judaism
Bioethics in the Boardroom - exploring ideas of managing bioethics issues.
Bruce W. Jenett, co-chair of the life sciences national practice group, Heller Ehrman White & McAuliffe, LLP
Elizabeth A. Price, leader of the life sciences product liability litigation team, Alston & Bird LLP
Eric Meslin, Ph.D., M.D., director of the Indiana University Center for Bioethics and assistant dean for bioethics, Indiana University
Rick Warner, senior vice president, Summit Global Partners
Paul Freiman, president and CEO, Neurobiological Technologies, Inc.
Lee W. Farrow, Esq., assistant vice president, CNA HealthPro
The Value of Innovation: Is What We’re Paying for New Drugs Worth It? - discussing the balance between innovative R&D and rising health-care costs.
Fred Telling, Ph.D., vice president of corporate policy and strategic management, Pfizer
Frank Lichtenberg, Ph.D., Graduate School of Business, Columbia University
Ernie Berndt, Ph.D., School of Management, Massachusetts Institute of Technology
Kevin Murphy, Ph.D., George Pratt Shultz Professor of Economics and Industrial Relations, Graduate School of Business, University of Chicago
Robert Topel, Ph.D., Isidore Brown and Gladys J. Brown Professor in Urban and Labor Economics, Graduate School of Business, University of Chicago
Tomas Philipson, Ph.D., Harris Graduate School of Public Policy, University of Chicago
Product Development Through Public/Private Partnerships - success stories and creative opportunities with public and private resources.
Steven M. Ferguson, deputy director of the division of technology development and transfer, Office of Technology Transfer, National Institutes of Health
Maria C. Freire, Ph.D., CEO, Global Alliance For TB Drug Development
Tuah Jenta, Ph.D., vice president of strategic alliances, Sarawak MediChem Pharmaceuticals, Inc.
Lita Nelsen, Technology Licensing Office, Massachusetts Institute of Technology
Pharmaceutical Price Controls: Lessons from Canada and the EU - discussing the effects of pricing regulations on consumers in developed countries.
Richard Manning, director of economic and science policy, Pfizer
John R. Graham, The Fraser Institute
Henry Grabowski, Ph.D., Duke University
Jack Calfee, Ph.D., American Enterprise Institute
BIO 2002 registration for approved, credentialed media is complimentary, and advance registration is encouraged. All freelancers must register in advance. To register please visit www.bio.org. In order to ensure housing, reporters are urged to register as soon as possible.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
# # #